234 related articles for article (PubMed ID: 31644324)
1. Impact of Increasing Wait Times on Overall Mortality of Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma: A Discrete Event Simulation Model.
Tully S; Feng Z; Grindrod K; McFarlane T; Chan KKW; Wong WWL
JCO Clin Cancer Inform; 2019 Oct; 3():1-9. PubMed ID: 31644324
[TBL] [Abstract][Full Text] [Related]
2. CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion.
Boeri M; Purdum AG; Sutphin J; Hauber B; Kaye JA
Future Oncol; 2021 Dec; 17(34):4697-4709. PubMed ID: 34581197
[TBL] [Abstract][Full Text] [Related]
3. Value of Reducing Wait Times for Chimeric Antigen Receptor T-Cell Treatment: Evidence From Randomized Controlled Trial Data on Tisagenlecleucel for Diffuse Large B-Cell Lymphoma.
Chen AJ; Zhang J; Agarwal A; Lakdawalla DN
Value Health; 2022 Aug; 25(8):1344-1351. PubMed ID: 35341689
[TBL] [Abstract][Full Text] [Related]
4. Rapid and sustained response to Chimeric Antigen Receptor T cell therapy in double hit diffuse large B cell lymphoma.
Deol A; Uberti J
Am J Hematol; 2020 Mar; 95(3):333-334. PubMed ID: 31429117
[No Abstract] [Full Text] [Related]
5. Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma.
Qasrawi A; Arora R; Ramlal R; Munker R; Hildebrandt GC
Am J Hematol; 2020 Apr; 95(4):E89-E91. PubMed ID: 31919891
[No Abstract] [Full Text] [Related]
6. Chimeric antigen receptor T-cell therapy's role in antiphospholipid syndrome: a case report.
Schmelz JL; Navsaria L; Goswamy R; Chuang HH; Miranda RN; Lee HJ
Br J Haematol; 2020 Feb; 188(3):e5-e8. PubMed ID: 31721157
[No Abstract] [Full Text] [Related]
7. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA
Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858
[TBL] [Abstract][Full Text] [Related]
8. Combination of chidamide and PD-1 blockade in Refractory/Relapsed aggressive large B-cell lymphomas with high risk of failing CAR-T therapy.
Wang Z; Xu H; Mei Y; Xiao M; Cao Y; Huang L; Yang Z; Zhang Y; Han Z; Zheng M; Hong Z
Int Immunopharmacol; 2024 May; 133():112014. PubMed ID: 38615378
[TBL] [Abstract][Full Text] [Related]
9. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL; Ghobadi A; Jacobson CA; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy A; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Wiezorek JS; Navale L; Xue A; Jiang Y; Bot A; Rossi JM; Kim JJ; Go WY; Neelapu SS
Lancet Oncol; 2019 Jan; 20(1):31-42. PubMed ID: 30518502
[TBL] [Abstract][Full Text] [Related]
11. The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
Lutfi F; Holtzman NG; Kansagra AJ; Mustafa Ali M; Bukhari A; Yan J; Samanta S; Gottlieb D; Kim DW; Matsumoto LR; Gahres N; Ruehle K; Lee ST; Law JY; Kocoglu MH; Atanackovic D; Yared JA; Hardy NM; Molitoris J; Mohindra P; Rapoport AP; Dahiya S
Br J Haematol; 2021 Nov; 195(3):405-412. PubMed ID: 34500492
[TBL] [Abstract][Full Text] [Related]
12. CAR T-cell Therapy for Diffuse Large B-cell Lymphoma in Canada: A Cost-Utility Analysis.
Masucci L; Tian F; Tully S; Feng Z; McFarlane T; Chan KKW; Wong WWL
Med Decis Making; 2024 Apr; 44(3):296-306. PubMed ID: 38486447
[TBL] [Abstract][Full Text] [Related]
13. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
14. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
15. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.
Qu C; Ping N; Kang L; Liu H; Qin S; Wu Q; Chen X; Zhou M; Xia F; Ye A; Kong D; Li C; Yu L; Wu D; Jin Z
J Immunother; 2020 Jan; 43(1):32-37. PubMed ID: 31219975
[TBL] [Abstract][Full Text] [Related]
16. Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment.
Mihăilă RG
Recent Pat Anticancer Drug Discov; 2019; 14(4):312-323. PubMed ID: 31642414
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
Locke FL; Neelapu SS; Bartlett NL; Siddiqi T; Chavez JC; Hosing CM; Ghobadi A; Budde LE; Bot A; Rossi JM; Jiang Y; Xue AX; Elias M; Aycock J; Wiezorek J; Go WY
Mol Ther; 2017 Jan; 25(1):285-295. PubMed ID: 28129122
[TBL] [Abstract][Full Text] [Related]
18. Unexpected neurologic complications following a novel lymphoma treatment 'expected' to give rise to neurologic toxicity.
Kersten MJ; van Ettekoven CN; Heijink DM
BMJ Case Rep; 2019 Nov; 12(11):. PubMed ID: 31722870
[TBL] [Abstract][Full Text] [Related]
19. Survival of patients with transformed lymphoma in the rituximab era.
Guirguis HR; Cheung MC; Piliotis E; Spaner D; Berinstein NL; Imrie K; Zhang L; Buckstein R
Ann Hematol; 2014 Jun; 93(6):1007-14. PubMed ID: 24414374
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone.
Chen YB; Hochberg EP; Feng Y; Neuberg D; Rawal B; Motyckova G; Fisher DC; McAfee SL; Spitzer TR; Lacasce AS
Leuk Lymphoma; 2010 May; 51(5):789-96. PubMed ID: 20367136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]